Product Description
3VM1001 is a topical cream that may be useful for the treatment of chronic osteoarthritis of the knee.
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: CDA Research Group, Inc.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Osteoarthritis
Phase 1: Neuralgia, Postherpetic|Osteoarthritis, Knee|Chronic Pain
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03421613 |
PHN | P1 |
Completed |
Neuralgia, Postherpetic |
2018-03-30 |
2019-03-22 |
Treatments |
|
NCT02332148 |
3VM0115 | P1 |
Unknown status |
Osteoarthritis, Knee|Chronic Pain |
2015-10-01 |
2019-03-20 |
Treatments |
|
NCT03142178 |
3VM1216 | P2 |
Completed |
Osteoarthritis |
2018-01-30 |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|